Saliva-Based Test Proposed to Diagnose Alzheimer’s, Mild Cognitive Impairment

Saliva-Based Test Proposed to Diagnose Alzheimer’s, Mild Cognitive Impairment
A new test using patients’ saliva may be helpful in distinguishing between Alzheimer’s, mild cognitive impairment, and normal brain function, new research reports. The study, “Alzheimer’s Biomarkers From Multiple Modalities Selectively Discriminate Clinical Status: Relative Importance of Salivary Metabolomics Panels, Genetic, Lifestyle, Cognitive, Functional Health and Demographic Risk Markers,” was published in Frontiers in Aging Neuroscience. Recent projections show that the worldwide incidence of dementia-related neurodegenerative diseases, especially Alzheimer’s disease, is increasing dramatically. Also, clinical trials have yet to produce successful therapeutics to reverse or prevent the course of neurodegeneration-related dementia in aging after diagnosis. Consequently, research and clinical attention has shifted to identifying possible risk factors prior to the development of symptoms to promote early management of Alzheimer’s. “So far, no disease-altering interventions for Alzheimer's disease have been successful,” Roger Dixon, PhD, University of Alberta, said in a press release. “For this reason, researchers are aiming to discover the earliest signals of the disease so that prevention protocols can be implemented.” To this end, researchers have been trying to identify biomarkers — measurable indicators of disease — in
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *